Cargando…
Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering
Molecularly targeted agent (MTA) combination therapy is in the early stages of development. When using a fixed dose of one agent in combinations of MTAs, toxicity and efficacy do not necessarily increase with an increasing dose of the other agent. Thus, in dose-finding trials for combinations of MTA...
Autores principales: | Guo, Beibei, Li, Yisheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359011/ https://www.ncbi.nlm.nih.gov/pubmed/25413162 http://dx.doi.org/10.1002/sim.6376 |
Ejemplares similares
-
Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship
por: Guo, Beibei, et al.
Publicado: (2014) -
A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation
por: Xu, Jin, et al.
Publicado: (2022) -
Modern dose-finding designs for cancer phase I trials: drug combinations and molecularly targeted agents
por: Hirakawa, Akihiro, et al.
Publicado: (2018) -
Efficient Bayesian inference for stochastic agent-based models
por: Jørgensen, Andreas Christ Sølvsten, et al.
Publicado: (2022) -
Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
por: Le Tourneau, Christophe, et al.
Publicado: (2012)